Novo looks at Victoza in fatty liver disease; FDA flags SGLT2 inhibitors for potentially high blood acid levels;

> Novo Nordisk ($NVO) is examining recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease. Report

> A new lawsuit claims Blue Cross has withheld hep C cure Harvoni for financial reasons. Release

> The FDA has warned that a new class of Type 2 diabetes drugs--SGLT2 inhibitors--may cause dangerously high levels of blood acids that could require hospitalization. Report

> A lawsuit claims the FDA overstepped its bounds by deciding two generic drugs used to treat ADHD should no longer be substituted for Johnson & Johnson's ($JNJ) widely used Concerta. More

> Boehringer Ingelheim has new Phase II study data for idiopathic pulmonary fibrosis (IPF) treatment Ofev that show its efficacy and safety in a broader range of patients. More

And Finally... Australia's Sirtex may be on Bayer's M&A radar as the two companies focus in on radiation treatments for liver cancers. Story

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?